TET2 promotes anti-tumor immunity by governing G-MDSCs and CD8+ T-cell numbers

EMBO Rep. 2020 Oct 5;21(10):e49425. doi: 10.15252/embr.201949425. Epub 2020 Sep 14.

Abstract

The host immune response is a fundamental mechanism for attenuating cancer progression. Here we report a role for the DNA demethylase and tumor suppressor TET2 in host anti-tumor immunity. Deletion of Tet2 in mice elevates IL-6 levels upon tumor challenge. Elevated IL-6 stimulates immunosuppressive granulocytic myeloid-derived suppressor cells (G-MDSCs), which in turn reduce CD8+ T cells upon tumor challenge. Consequently, systematic knockout of Tet2 in mice leads to accelerated syngeneic tumor growth, which is constrained by anti-PD-1 blockade. Removal of G-MDSCs by the anti-mouse Ly6g antibodies restores CD8+ T-cell numbers in Tet2-/- mice and reboots their anti-tumor activity. Importantly, anti-IL-6 antibody treatment blocks the expansion of G-MDSCs and inhibits syngeneic tumor growth. Collectively, these findings reveal a TET2-mediated IL-6/G-MDSCs/CD8+ T-cell immune response cascade that safeguards host adaptive anti-tumor immunity, offering a cell non-autonomous mechanism of TET2 for tumor suppression.

Keywords: IL-6; Tet2; anti-tumor immune response; granulocytic myeloid-derived suppressor cells; syngeneic tumor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptive Immunity
  • Animals
  • CD8-Positive T-Lymphocytes
  • Cell Count
  • DNA-Binding Proteins / genetics
  • Dioxygenases
  • Mice
  • Myeloid-Derived Suppressor Cells*
  • Neoplasms* / genetics
  • Proto-Oncogene Proteins / genetics

Substances

  • DNA-Binding Proteins
  • Proto-Oncogene Proteins
  • Dioxygenases
  • Tet2 protein, mouse

Associated data

  • GEO/GSE144787